secwatch.observer — SEC 8-K summary
======================================

Issuer:     Disc Medicine, Inc. (IRON)
CIK:        0001816736
Form:       8-K
Filed at:   2023-01-23T23:59:59+00:00
Accession:  0001193125-23-012530
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Disc Medicine licenses anti-TMPRSS6 antibodies from Mabwell; $10M upfront, up to $412.5M milestones
--------------------------------------------------------------------------------

- Exclusive license to MWTX-003 and other anti-TMPRSS6 mAbs for US, Europe, and territories outside Greater China and SE Asia.
- Upfront cash payment of $10M; total potential milestones up to $412.5M; tiered mid-to-high single-digit royalties on net sales.
- MWTX-003 is phase 1-ready with FDA IND accepted; Disc plans to start phase 1 in healthy volunteers in H2 2023.
- Antibodies target TMPRSS6 to modulate iron homeostasis, with potential in beta-thalassemia and polycythemia vera.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1816736/000119312523012530/0001193125-23-012530-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1816736/000119312523012530/d447304d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-012530

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer